Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-862-8 | CAS number: 111-36-4
Endpoint summary
Administrative data
Description of key information
acute oral toxicity: LD50 = 360 mg/kg bw (rat, male)
acute dermal toxicity: ALD = 700 mg/kg bw (ALD = The lowest dose at which one or more animals died)
acute inhalation toxicity: LC50 = 59 mg/m³ (rat, male+female)
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 360 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Dose descriptor:
- LC50
- Value:
- 59 mg/m³
Acute toxicity: via dermal route
Endpoint conclusion
- Dose descriptor:
- discriminating dose
- Value:
- 700 mg/kg bw
Additional information
The oral LD50 was determined to be 360 mg/kg bw for rats. Toxic symptoms included apathy, stiff gait, and labored breathings. Acute inhalation toxicity studies revealed that n-butyl isocyanate is highly toxic when inhaled. The LC50 (rat, 4h) value reported in a study according to OECD TG 403 with vapor inhalation is 59 mg/m³. Assessment of the acute inhalation toxicity data indicates that the primary toxic effects in response to exposure to evaporated n-butyl isocyanate are focused on the portal of entry, the respiratory tract. Thus death is due to severe respiratory tract lesions. Special investigations with male rats revealed overt inflammatory responses in the lung, which also could be confirmed histopathologically. The prominent microscopic changes were increased number of macrophages, perivascular round-cell infiltration, focal fibroproliferative reactions, emphysema, thickening septa, and abscessive pneumonia. Inflammation of the airways became prominent after exposure of a lethal concentration (50 mg/m³, 1x4h) and was marginally pronounced at a sublethal concentration (25 mg/m³, 1x4h)). No significant changes other than transient clinical signs were observed at 8 mg/m³. Ca. 3 mg/m³ were tolerated without any symptoms. For acute dermal toxicity only not assignable/invalid studies are available.
Justification for classification or non-classification
For the acute oral toxicity Xn, R22 is justified as a result of the LD50 = 360 mg/kg bw
For the acute inhalation toxicity T+, R26 is justified as a result of the LC50 = 59 mg/m³ air
In addition, several studies reported respiration irritational effects. Therefore R 37 is applicable
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
